global framework
GSK set to receive over $500M from mRNA patent settlement tied to BioNTech–CureVac–Pfizer deal
GSK; CureVac; BioNTech; Pfizer; mRNA patents; settlement; royalties; COVID-19 vaccine; influenza vaccine; combination vaccines; licensing; upfront payment; US litigation; global framework; BioNTech acquisition of CureVac